Pharmacokinetic-Pharmacodynamic Modeling of the In Vitro Activities of Oxazolidinone Antimicrobial Agents against Methicillin-Resistant Staphylococcus aureus
- 1 December 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (12), 5039-5045
- https://doi.org/10.1128/aac.00633-09
Abstract
Linezolid is the first FDA-approved oxazolidinone with activity against clinically important gram-positive pathogens, including methicillin (meticillin)-resistant Staphylococcus aureus (MRSA). RWJ-416457 is a new oxazolidinone with an antimicrobial spectrum similar to that of linezolid. The goal of the present study was to develop a general pharmacokinetic (PK)-pharmacodynamic (PD) model that allows the characterization and comparison of the in vitro activities of oxazolidinones, determined in time-kill curve experiments, against MRSA. The in vitro activities of RWJ-416457 and the first-in-class representative, linezolid, against MRSA OC2878 were determined in static and dynamic time-kill curve experiments over a wide range of concentrations: 0.125 to 8 μg/ml (MIC, 0.5 μg/ml) and 0.25 to 16 μg/ml (MIC, 1 μg/ml), respectively. After correction for drug degradation during the time-kill curve experiments, a two-subpopulation model was simultaneously fitted to all data in the NONMEM VI program. The robustness of the model and the precision of the parameter estimates were evaluated by internal model validation by nonparametric bootstrap analysis. A two-subpopulation model, consisting of a self-replicating, oxazolidinone-susceptible and a persistent, oxazolidinone-insusceptible pool of bacteria was appropriate for the characterization of the time-kill curve data. The PK-PD model identified was capable of accounting for saturation in growth, delays in the onsets of growth and drug-induced killing, as well as naturally occurring bacterial death. The simultaneous fit of the proposed indirect-response, maximum-effect model to the data resulted in concentrations that produced a half-maximum killing effect that were significantly ( P < 0.05) lower for RWJ-416457 (0.41 μg/ml) than for linezolid (1.39 μg/ml). In combination with the appropriate PK data, the susceptibility-based two-subpopulation model identified may provide valuable guidance for the selection of oxazolidinone doses or dose regimens for use in clinical studies.This publication has 31 references indexed in Scilit:
- Comparative time–kill study of doxycycline, tigecycline, sulbactam, and imipenem against several clones of Acinetobacter baumanniiDiagnostic Microbiology and Infectious Disease, 2008
- Pharmacokinetic–Pharmacodynamic Modeling and Simulation for in Vivo Bactericidal Effect in Murine Infection ModelJournal of Pharmaceutical Sciences, 2008
- Painful neuropathy with skin denervation after prolonged use of linezolidJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Integration of pharmacokinetic/pharmacodynamic modeling and simulation in the development of new anti-infective agents – minimum inhibitory concentration versus time-kill curvesExpert Opinion on Drug Discovery, 2007
- In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and EnterococciAntimicrobial Agents and Chemotherapy, 2007
- In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457Antimicrobial Agents and Chemotherapy, 2007
- Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve ExperimentsAntimicrobial Agents and Chemotherapy, 2007
- The importance of the development of antibiotic resistance in Staphylococcus aureusClinical Microbiology & Infection, 2006
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an updateJournal of Antimicrobial Chemotherapy, 2005
- Application of Logistic Growth Model to Pharmacodynamic Analysis of in Vitro Bactericidal KineticsJournal of Pharmaceutical Sciences, 1998